Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The Download: metric weaknesses and AI elephant warnings

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: metric weaknesses and AI elephant warnings Date: 2026-06-29 12:10 Source: https://www.technologyreview.com/2026/06/29/1139834/the-download-metric-weaknesses-ai-elephant-warnings/ <p><em>This is today’s edition of </em><a href="https://forms.technologyreview.com/n…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There have been some 3,000 human casualties from human-elephant conflicts in India in the last five years, and over 1,000 elephant deaths since 2014.

    60% confidence
  • Research shows Gen Z are more likely to believe and pass on misinformation when they feel a sense of common identity with the person who shared it, with social media shifting credibility from community to identity-based authority.

    60% confidence
  • Zhipu AI's model still cannot match Anthropic or OpenAI on general tasks despite matching Mythos in security bug detection.

    60% confidence
  • India is home to about 60% of the world's wild Asian elephants, with around 80% of their habitat outside protected areas, leading to deadly human-wildlife conflicts.

    60% confidence
  • External metrics and data can never capture what is truly important; worse, they inevitably redefine one's core sense of what is important, whether or not one is aware of the trap.

    60% confidence
  • A new study suggests 6.4 to 7.8 hours of sleep is the optimal range; too much sleep may be as harmful as too little.

    60% confidence
  • Google capping Meta's access to Gemini AI compute has disrupted and delayed some Meta AI projects.

    60% confidence
  • Powerful AI capable of altering the landscape of cyberwarfare cannot remain solely in American hands; Chinese AI firms must match US capabilities.

    60% confidence
  • Appropriate safeguards are now in place for the release of Anthropic's Mythos 5 model to trusted organizations.

    60% confidence
  • Security researchers say Zhipu AI is poised to reset the AI race after its model matched Anthropic's Mythos in finding security bugs.

    60% confidence
  • Android phones gave Venezuelan earthquake victims between seconds and up to two minutes of advance notice before the seismic events struck.

    60% confidence
  • US restrictions on AI models have sparked alarm that they are boosting China's AI progress.

    60% confidence
  • Chipmakers are profiting off AI at the expense of everyone else.

    60% confidence
  • Severe weather is now the leading cause of loss for data centers, as extreme heat puts AI-heavy data centers under significant operational pressure.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com